ORTX - Orchard Therapeutics' MLD gene therapy wins European nod

Orchard Therapeutics (ORTX) +4% premarket, after the European Commission ((EC)) approves Libmeldy, gene therapy for the treatment of metachromatic leukodystrophy ((MLD)), a rare genetic condition caused by mutations in the ARSA gene, characterized by accumulation of fats called sulfatides, which causes the destruction of the protective fatty layer surrounding the nerves in both the central and the peripheral nervous system.Last, the company received FDA clearance for Libmeldy's(OTL-200) Investigational New Drug application.

For further details see:

Orchard Therapeutics' MLD gene therapy wins European nod